Psychiatr. pro Praxi, 2002; 3: 94-101

Místo stabilizátorů nálady v léčbě bipolární poruchy

MUDr. Erik Herman1,3,2, doc. MUDr. Ján Praško CSc4,6,5,7, MUDr. Jiří Hovorka CSc2,8
1 Psychiatrická klinika 1. LF UK a VFN Praha
2 Neurologické oddělení, neuropsychiatrické a epileptologické centrum, Nemocnice Na Františku s poliklinikou, Praha
3 Psychiatrická ambulance, Praha
4 Psychiatrické centrum Praha, 3. LF UK, Praha
5 Centrum neuropsychiatrických studií, Praha
6 Psychiatrická klinika FN a LF UP, Olomouc
7 3. LF UK, Praha
8 Neurochirurgická klinika 1. LF UK, Praha

Keywords: bipolar spectrum, mood stabilizer, lithium, valproate, carbamazepine, lamotrigine.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Herman E, Praško J, Hovorka J. Místo stabilizátorů nálady v léčbě bipolární poruchy. Psychiatr. praxi. 2002;3(3):94-101.

Autoři popisují širší koncepci bipolárního spektra a užití stabilizátorů nálady v léčbě manické a depresivní epizody i profylaktické léčby bipolární poruchy. Diskutovány jsou terapeutické postupy i zvládání vedlejších účinků akutní i dlouhodobé léčby především lithiem, karbamazepinem a valproátem.

The place of mood stabilizers in the treatment of bipolar disorder

The broader concept of bipolar spectrum is introduced. Described is the treatment of manic, depressive and prophylactic treatment of bipolar disorder especially with lithium, valproate and carbamazepine, as well the management of adverse effects of this drugs.

Psychiatrická ambulance Praha

Psychiatrická klinika 1. lékařské fakulty Univerzity Karlovy Praha

Neurologické oddělení a Neuropsychiatrické centrum Nemocnice Na Františku Praha

Psychiatrické centrum Praha

III. lékařská fakulta Univerzity Karlovy Praha

Neurochirurgická klinika 1. lékařské fakulty Univerzity Karlovy Praha

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Akiskal HS. Mood disorders: Clinical Features. In: Sadock BJ, Sadock VA. (ed.) Kaplan & Sadock Comprehensive textbook of psychiatry. Philadelphia: Lippincott Williams & Wilkins 2000: 362-1365.
    2. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry 1995; 152: 8: 1130-1138. Go to original source... Go to PubMed...
    3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association 1994.
    4. Baldessarini RJ. A plea for integrity of the bipolar disorder concept. Bipolar Disorder 2000; 2: 3-7. Go to original source... Go to PubMed...
    5. Bourgeois M, Hantouche E, Akiskal HS. The EPIMAN and EPIDEP French studies of bipolarity. J. Bipolar Disorder 1997; 1: 13-19.
    6. Calabrese JR, Bowden ChL, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J. Clin. Psychiatry 1999; 60: 2: 79-88. Go to original source... Go to PubMed...
    7. Češková E. Nedoceněný valproát? Čes a slov Psychiat 2001; 97: 64-68.
    8. Goodwin FK, Jamison KR. Manic-Depressive Illness. Oxford University Press 1990.
    9. Herman E, Hovorka J, Syrovátka J, Němcová I. Lamotrigin jako stabilizátor nálady v léčbě pacientů s bipolární poruchou typu II. Čes a slov Psychiat 2002; 98, 1: 8-14.
    10. Jacobson JL. Mood-stabilizing agents. In: Jacobson JL, Jacobson AM. (ed.) Psychiatric secrets, Hanley and Belfus, Philadelphia 2001.
    11. Janicak PG. Treatment with mood stabilizers. In: Janicak PG. Handbook of psychopharmacotherapy, Lippincott Williams and Wilkins, Baltimore: 1999; 215-251.
    12. Keller MB, Lavori PW, Kane JM, Gelenberg AJ, Rosenbaum JF, Waltzer EA, Baker LA. Subsyndromal symptoms in bipolar disorder. A Comparison of standard and low serum levels of lithium. Arch Gen Psychiatry 1992; 49: 371-376. Go to original source... Go to PubMed...
    13. Klerman GL. The spectrum of mania. Compr Psychiatry 1981; 22: 11-20. Go to original source... Go to PubMed...
    14. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 1: 30-35. Go to original source... Go to PubMed...
    15. Nemeroff ChB, Evans DL, Gyulai L, Sachs GS, Bowden ChB, Gergel IP, Oakes R, Pitts CD. Double-blind, placebo controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906-912. Go to original source... Go to PubMed...
    16. Post RM. Mood disorders: Treatment of bipolar disorders. In: Sadock BJ, Sadock VA. (ed.) Kaplan & Sadock Comprehensive textbook of psychiatry. Philadelphia: Lippincott Williams & Wilkins 2000; 362-1365.
    17. Sachs GR, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF. A double-blind trial of bupropion versus desipramine for bipolar disorder. J Clin Psychiatry 1994; 55: 391-393.
    18. Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP. Medication treatment of bipolar disorder 2000. Postgraduate Medicine Special Report April 2000.
    19. Švestka J. Nová psychofarmaka: Antiepileptika III. generace a jejich použití v psychiatrii. Psychiatrie 1998; 4: 250-262.
    20. Walden J, Grunze H. Bipolar affective disorder. Etiology and treatment. Georg Thieme Verlag, Stuttgart 2000.
    21. Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145: 2: 179-184. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.